Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now

Autores
Perazzo, Priscila; Eguibar, Nair; Gonzalez, Rodrigo Horacio; Nusblat, Alejandro David; Cuestas, María Luján
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver disease, clinical outcome and response to immune- and antiviral-therapy. Parameters associated with the host immune system (HBV specific T- and/or B-cell repertoires, defective antigen presentation and diminished Th1/Th2 response ratio) and viral factors such as the HBV genotypes and their evolving variants/mutants, have largely contributed to explaining such differences. The unique genomic structure and replication cycle of HBV provide much opportunity for mutations to occur in any of its genes undergoing selection pressures, such as those associated with the host immune system, the hepatitis B vaccine and/or hepatitis B immune globulin and the antiviral therapy with nucleos(t)ide analogues. Firstly, this review describes the current prevalence of S-escape mutants worldwide. Secondly, the clinical implications of such surface gene variants and the impact of universal hepatitis B vaccination on HBV mutations and genotypes are discussed. Finally, the fact that the immune escape process also extends well beyond HBV is addressed.

Fil: Perazzo, Priscila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
Fil: Eguibar, Nair. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
Fil: Gonzalez, Rodrigo Horacio. Universidad de Buenos Aires; Argentina
Fil: Nusblat, Alejandro David. Universidad de Buenos Aires; Argentina
Fil: Cuestas, María Luján. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
Materia
HBV
HBSAG
S-IMMUNE
ESCAPE
MUTANTS
HEPATITIS-B
VACCINE
OBI
HBIG
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/47548
Acceder
id CONICETDig_dc4feae610fcff094d018b8915fa182d
oai_identifier_str oai:ri.conicet.gov.ar:11336/47548
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until NowPerazzo, PriscilaEguibar, NairGonzalez, Rodrigo HoracioNusblat, Alejandro DavidCuestas, María LujánHBVHBSAGS-IMMUNEESCAPEMUTANTSHEPATITIS-BVACCINEOBIHBIGhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver disease, clinical outcome and response to immune- and antiviral-therapy. Parameters associated with the host immune system (HBV specific T- and/or B-cell repertoires, defective antigen presentation and diminished Th1/Th2 response ratio) and viral factors such as the HBV genotypes and their evolving variants/mutants, have largely contributed to explaining such differences. The unique genomic structure and replication cycle of HBV provide much opportunity for mutations to occur in any of its genes undergoing selection pressures, such as those associated with the host immune system, the hepatitis B vaccine and/or hepatitis B immune globulin and the antiviral therapy with nucleos(t)ide analogues. Firstly, this review describes the current prevalence of S-escape mutants worldwide. Secondly, the clinical implications of such surface gene variants and the impact of universal hepatitis B vaccination on HBV mutations and genotypes are discussed. Finally, the fact that the immune escape process also extends well beyond HBV is addressed.<br />Fil: Perazzo, Priscila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: Eguibar, Nair. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaFil: Gonzalez, Rodrigo Horacio. Universidad de Buenos Aires; ArgentinaFil: Nusblat, Alejandro David. Universidad de Buenos Aires; ArgentinaFil: Cuestas, María Luján. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; ArgentinaMedCrave2015-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/47548Perazzo, Priscila; Eguibar, Nair; Gonzalez, Rodrigo Horacio; Nusblat, Alejandro David; Cuestas, María Luján; Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now; MedCrave; Journal of Human Virology &Retrovirology; 2; 3; 4-2015; 46-552373-6453CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.15406/jhvrv.2015.02.00046info:eu-repo/semantics/altIdentifier/url/http://medcraveonline.com/JHVRV/JHVRV-02-00046.phpinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:37Zoai:ri.conicet.gov.ar:11336/47548instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:37.531CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
title Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
spellingShingle Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
Perazzo, Priscila
HBV
HBSAG
S-IMMUNE
ESCAPE
MUTANTS
HEPATITIS-B
VACCINE
OBI
HBIG
title_short Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
title_full Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
title_fullStr Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
title_full_unstemmed Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
title_sort Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now
dc.creator.none.fl_str_mv Perazzo, Priscila
Eguibar, Nair
Gonzalez, Rodrigo Horacio
Nusblat, Alejandro David
Cuestas, María Luján
author Perazzo, Priscila
author_facet Perazzo, Priscila
Eguibar, Nair
Gonzalez, Rodrigo Horacio
Nusblat, Alejandro David
Cuestas, María Luján
author_role author
author2 Eguibar, Nair
Gonzalez, Rodrigo Horacio
Nusblat, Alejandro David
Cuestas, María Luján
author2_role author
author
author
author
dc.subject.none.fl_str_mv HBV
HBSAG
S-IMMUNE
ESCAPE
MUTANTS
HEPATITIS-B
VACCINE
OBI
HBIG
topic HBV
HBSAG
S-IMMUNE
ESCAPE
MUTANTS
HEPATITIS-B
VACCINE
OBI
HBIG
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver disease, clinical outcome and response to immune- and antiviral-therapy. Parameters associated with the host immune system (HBV specific T- and/or B-cell repertoires, defective antigen presentation and diminished Th1/Th2 response ratio) and viral factors such as the HBV genotypes and their evolving variants/mutants, have largely contributed to explaining such differences. The unique genomic structure and replication cycle of HBV provide much opportunity for mutations to occur in any of its genes undergoing selection pressures, such as those associated with the host immune system, the hepatitis B vaccine and/or hepatitis B immune globulin and the antiviral therapy with nucleos(t)ide analogues. Firstly, this review describes the current prevalence of S-escape mutants worldwide. Secondly, the clinical implications of such surface gene variants and the impact of universal hepatitis B vaccination on HBV mutations and genotypes are discussed. Finally, the fact that the immune escape process also extends well beyond HBV is addressed.<br />
Fil: Perazzo, Priscila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
Fil: Eguibar, Nair. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
Fil: Gonzalez, Rodrigo Horacio. Universidad de Buenos Aires; Argentina
Fil: Nusblat, Alejandro David. Universidad de Buenos Aires; Argentina
Fil: Cuestas, María Luján. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones en Microbiología y Parasitología Médica. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones en Microbiología y Parasitología Médica; Argentina
description Despite of the progress made in vaccine and antiviral therapy development, hepatitis B virus (HBV) infection remains a major health care problem. More than 240 million people are chronically infected worldwide showing differences in the severity of liver disease, clinical outcome and response to immune- and antiviral-therapy. Parameters associated with the host immune system (HBV specific T- and/or B-cell repertoires, defective antigen presentation and diminished Th1/Th2 response ratio) and viral factors such as the HBV genotypes and their evolving variants/mutants, have largely contributed to explaining such differences. The unique genomic structure and replication cycle of HBV provide much opportunity for mutations to occur in any of its genes undergoing selection pressures, such as those associated with the host immune system, the hepatitis B vaccine and/or hepatitis B immune globulin and the antiviral therapy with nucleos(t)ide analogues. Firstly, this review describes the current prevalence of S-escape mutants worldwide. Secondly, the clinical implications of such surface gene variants and the impact of universal hepatitis B vaccination on HBV mutations and genotypes are discussed. Finally, the fact that the immune escape process also extends well beyond HBV is addressed.<br />
publishDate 2015
dc.date.none.fl_str_mv 2015-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/47548
Perazzo, Priscila; Eguibar, Nair; Gonzalez, Rodrigo Horacio; Nusblat, Alejandro David; Cuestas, María Luján; Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now; MedCrave; Journal of Human Virology &Retrovirology; 2; 3; 4-2015; 46-55
2373-6453
CONICET Digital
CONICET
url http://hdl.handle.net/11336/47548
identifier_str_mv Perazzo, Priscila; Eguibar, Nair; Gonzalez, Rodrigo Horacio; Nusblat, Alejandro David; Cuestas, María Luján; Hepatitis B Virus (HBV) and S-Escape Mutants: From the Beginning until Now; MedCrave; Journal of Human Virology &Retrovirology; 2; 3; 4-2015; 46-55
2373-6453
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.15406/jhvrv.2015.02.00046
info:eu-repo/semantics/altIdentifier/url/http://medcraveonline.com/JHVRV/JHVRV-02-00046.php
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv MedCrave
publisher.none.fl_str_mv MedCrave
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269414137790464
score 13.13397

Publicaciones similares